(NASDAQ: MBX) Mbx Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.89%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.67%.
Mbx Biosciences's revenue in 2025 is N/A.On average, 1 Wall Street analysts forecast MBX's revenue for 2028 to be $5,815,840,554, with the lowest MBX revenue forecast at $5,815,840,554, and the highest MBX revenue forecast at $5,815,840,554. On average, 2 Wall Street analysts forecast MBX's revenue for 2029 to be $10,882,975,198, with the lowest MBX revenue forecast at $1,477,357,198, and the highest MBX revenue forecast at $20,288,593,197.
In 2030, MBX is forecast to generate $22,037,857,653 in revenue, with the lowest revenue forecast at $7,308,907,207 and the highest revenue forecast at $36,766,808,100.